NASDAQ Soins de santé Biotechnologie TARS

Tarsus Pharmaceuticals, Inc.

$ 63.16 0.98 %

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

CEO: Bobak R. Azamian - https://www.tarsusrx.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$68 7.66 %

Recommandation

Buy

DCF

$ -450.07

Loading data...

TARS vs S&P500

Loading data...

No data available.

Quick ratio

3.71

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-56.90

may indicate that the company is undervalued or has poor growth prospects.

EPS

-1.11

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-14.19 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-11.54 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.72

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.25

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.73

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
7.47 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.71 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.15 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.